CETP inhibition in cardiovascular risk management: a critical appraisal
- 1 February 2007
- journal article
- review article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 37 (2), 90-98
- https://doi.org/10.1111/j.1365-2362.2007.01756.x
Abstract
In view of the cardioprotective effect of high-density lipoproteins (HDL) and the limited effects of statin and fibrate therapy on HDL cholesterol, it is clinically relevant to test whether pharmacological treatment aimed at raising HDL lowers cardiovascular risk. Cholesteryl ester transfer protein (CETP) is a new therapeutic target, because the cholesteryl ester transfer process lowers HDL cholesterol and contributes to an atherogenic lipoprotein profile, particularly when plasma triglycerides are high. Clinical evidence suggests that coronary artery calcification as well as intima media thickness is positively related to plasma cholesteryl ester transfer, and that high plasma CETP concentration is associated with increased cardiovascular risk in hypertriglyceridaemia. However, CETP could also have anti-atherogenic potential, since it provides a potentially beneficial route for delivery of HDL-derived cholesteryl esters to the liver. In addition, CETP could also favourably stimulate peripheral cell cholesterol removal and enhance hepatic cholesterol uptake. Recent evidence suggests that a high CETP level may confer lower cardiovascular risk in the context of low triglycerides. At maximal doses, the CETP inhibitors JTT-705 and torcetrapib elicit a marked rise in HDL cholesterol of up to 34% and 91-106%, respectively. The effectiveness of these drugs on (intermediate) clinical outcome measures is currently being tested in large-scale phase III clinical trials, with torcetrapib being only evaluated in combination therapy with atorvastatin. When and how to use CETP inhibitors, e.g. in combination with a statin or a fibrate, is a major challenge. We propose that low HDL cholesterol in the context of high triglycerides, such as found in type 2 diabetes mellitus, could become an important indication area for this new class of drugKeywords
This publication has 63 references indexed in Scilit:
- HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathwayJCI Insight, 2006
- Antibody against cholesteryl ester transfer protein (CETP) elicited by a recombinant chimeric enzyme vaccine attenuated atherosclerosis in a rabbit modelLife Sciences, 2005
- Effectiveness of Inhibition of Cholesteryl Ester Transfer Protein by JTT-705 in Combination With Pravastatin in Type II DyslipidemiaThe American Journal of Cardiology, 2005
- Lipid transfer proteins (LTP) and atherosclerosisAtherosclerosis, 2005
- Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin TreatmentCirculation, 2005
- Depletion of Pre-β-high Density Lipoprotein by Human Chymase Impairs ATP-binding Cassette Transporter A1- but Not Scavenger Receptor Class B Type I-mediated Lipid Efflux to High Density LipoproteinOnline Journal of Public Health Informatics, 2004
- Natural genetic variation as a tool in understanding the role of CETP in lipid levels and diseaseJournal of Lipid Research, 2003
- Phospholipid transfer proteinCurrent Opinion in Lipidology, 2002
- Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene.JCI Insight, 1995
- Prevalence of risk factors in men with premature coronary artery diseaseThe American Journal of Cardiology, 1991